MCK

McKesson Corporation (MCK) | Rumor.io

McKesson

MCK

Attention (50-day avg)0%

Attention rank (50-day avg)#1,860

Bullish sentiment (50-day avg)80%

Price to earnings ratio23.1

Market capitalization99.8B

Earnings per share37.3

Dividend yield (TTM)0.44%

Revenue (annual)403.4B

Net income (annual)5.1B

Social

What share of all stock conversation is about MCK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 25

McKesson ($MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion to expand its clinical research and biopharma commercialization services.
The acquisition will enhance McKesson's Oncology & Multispecialty segment and position the company for growth in the $25 billion oncology market.
McKesson's shares rose to a session high after the announcement, with the company's quarterly dividend increased 15% and Barclays raising its price target to $1,000.

Generated by AI

Sentiment

Of the messages about MCK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +18.87	74.33% -17.71
Bearish	—	—	0% -18.87	25.67% +17.71

Bullish· Feb 5

McKesson Corporation (MCK) has delivered a strong Q3 FY26, beating EPS expectations and raising full-year guidance to $38.80-$39.20, driven by robust growth in oncology and biopharma services.
The company's quarterly print and guide-up have driven the stock's move, with a solid North American distribution and strong revenue and margin performance.
MCK has been on a remarkable upward trajectory since 2019, with a +1,000% increase, and is expected to continue its strong momentum, with a high likelihood of reaching new all-time highs.

Bearish· Aug 8

McKesson Corporation's ($MCK) recent performance has been marked by a significant decline, with its market cap loss reaching $9.6B.
The company's revenue has missed expectations, with a 3.91% miss in 1Q25, and its top line guide has been reset.
McKesson's stock has experienced a substantial drop, with its worst day in 9 years, and its shares have fallen by -11.3% in one day.

Generated by AI

Topics

Of the messages about MCK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.67%	28.92%
Technical Analysis	—	—	13.33%	16.74%
Analysts	—	—	0%	8.1%
Earnings	—	—	0%	32.75%
Controversies	—	—	13.33%	0.68%
Macro	—	—	6.67%	12.81%

Earnings· Feb 7

McKesson Corporation reported Q3 2024 earnings, with adjusted EPS of $7.74 beating the estimate of $7.05.
Revenue for the quarter was $80.9B, beating the estimated $77.86B.
The company raised its full-year guidance for adjusted EPS to $27.25-$27.65, from the previous estimate of $26.80-$27.40.

Analysts· Dec 9

Bank of America raised McKesson's PT to $265 with a buy rating.
Barclays analyst Steve Valiquette maintained McKesson with an Overweight rating and raised the price target from $270 to $290.
Robert W. Baird raised McKesson's PT to $300 with an outperform rating.

Announcements· May 7

McKesson Corporation reported Q1 2024 earnings with revenues at $76.4 billion, missing the estimated $79.17 billion.
The company's adjusted EPS came in at $6.18, below the estimated $6.31.
McKesson's stock price declined by 1.05% in after-hours trading following the earnings release.

Controversies· Jul 20

McKesson Corporation ($MCK) is involved in a $1.1 billion opioid settlement with New York Attorney General.
$MCK and other distributors are near a $26 billion opioid settlement with the US government.
McKesson ($MCK) is mentioned alongside Johnson & Johnson (JNJ) as a favored stock on the Street due to the impending settlement.

Technical Analysis· Oct 26

The current level of support for MCK is around $146.74, with a deeper support level at $145.13.
MCK's level of support at $145.37 was defended, but the daily support level at $145.13 remains a concern.
The LOD (low of the day) for MCK is $147.26, which is a key level to watch for potential support.

Generated by AI

Community

Of the messages about MCK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	20.75%	36.82%
Newcomers	—	—	79.25%	63.18%

Regulars· Feb 4

McKesson Corporation's Q3 2026 earnings report exceeded expectations, with revenue of $106.2 billion, a 11% year-over-year increase, and adjusted earnings per share (EPS) of $9.34, a 16% year-over-year increase.
The company's GAAP EPS was $9.59, a 38% increase year-over-year, and its quarterly consolidated revenues of $106.2 billion increased 11% year-over-year.
McKesson raised its fiscal year 2026 adjusted EPS guidance to $38.80-$39.20, a 17-19% growth, following the strong Q3 earnings report, driven by surging oncology growth and consistent execution.

Newcomers· Jan 30

The newcomer is impressed by MCK's performance in a down market, citing its oligopoly status as a reason for its success.
The newcomer has invested in MCK due to its large total addressable market (TAM) and monopoly-like market position, which is expected to drive accelerating revenue and expanding margins.
MCK's position as the #1 seat at the table in its oligopoly is seen as a key factor in its unfair advantage, making it an attractive investment opportunity.

Generated by AI

McKesson (NYSE:MCK) has outperformed the market over the past 5 years by 22.21% on an annualized basis producing an average annual return of 34.23%. Currently, McKesson has a market capitalization of $102.91 billion.

5d agoBenzinga

Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?

CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.

5d agoYahoo Finance UK

Why McKesson (MCK) Dipped More Than Broader Market Today

The latest trading day saw McKesson (MCK) settling at $880.5, representing a -1.2% change from its previous close.

6d agoYahoo Finance

McKesson Corp. stock outperforms competitors despite losses on the day

6d agomarketwatch.com

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

6d agofinance.yahoo.com

Also Discussed

Investors talking about MCK also mention

#	Name	Attention
1	ABC - AmerisourceBergen Corporation	——
2	Cardinal Health Inc.CAH	0%new
3	Veradigm Inc.MDRX	0%0
4	U.S. BancorpUSB	0%new
5	The Cigna GroupCI	0%0
6	CVS Health CorporationCVS	0%0
7	HCA Healthcare Inc.HCA	0%0
8	McCormick & Company, IncorporatedMKC	0%0
9	LUXH - LuxUrban Hotels Inc.	——
10	Elevance Health, Inc.ELV	0%new

McKesson Corporation

Healthcare
Medical Distribution

McKesson Corporation is a healthcare services company that supports the flow of medicines, supplies, and related solutions across the healthcare system. The company operates through North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions, serving pharmacies, health systems, physician practices, post-acute care providers, and other care settings. Its pharmaceutical distribution business supplies branded, generic, specialty, biosimilar, and over-the-counter products, while its medical-surgical operations provide clinical supplies, logistics, and equipment support. McKesson also offers technology-enabled services that help healthcare organizations manage prescriptions, practice operations, and patient care workflows. Through its broad distribution network and service platforms, McKesson plays a central role in connecting manufacturers, providers, and pharmacies across the U.S. and internationally.

Website

Location

6555 State Highway 161

Irving, TX, 75039

United States

Social

What share of all stock conversation is about MCK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 25

McKesson ($MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion to expand its clinical research and biopharma commercialization services.
The acquisition will enhance McKesson's Oncology & Multispecialty segment and position the company for growth in the $25 billion oncology market.
McKesson's shares rose to a session high after the announcement, with the company's quarterly dividend increased 15% and Barclays raising its price target to $1,000.

Generated by AI

Sentiment

Of the messages about MCK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +18.87	74.33% -17.71
Bearish	—	—	0% -18.87	25.67% +17.71

Bullish· Feb 5

McKesson Corporation (MCK) has delivered a strong Q3 FY26, beating EPS expectations and raising full-year guidance to $38.80-$39.20, driven by robust growth in oncology and biopharma services.
The company's quarterly print and guide-up have driven the stock's move, with a solid North American distribution and strong revenue and margin performance.
MCK has been on a remarkable upward trajectory since 2019, with a +1,000% increase, and is expected to continue its strong momentum, with a high likelihood of reaching new all-time highs.

Bearish· Aug 8

McKesson Corporation's ($MCK) recent performance has been marked by a significant decline, with its market cap loss reaching $9.6B.
The company's revenue has missed expectations, with a 3.91% miss in 1Q25, and its top line guide has been reset.
McKesson's stock has experienced a substantial drop, with its worst day in 9 years, and its shares have fallen by -11.3% in one day.

Generated by AI

Topics

Of the messages about MCK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	66.67%	28.92%
Technical Analysis	—	—	13.33%	16.74%
Analysts	—	—	0%	8.1%
Earnings	—	—	0%	32.75%
Controversies	—	—	13.33%	0.68%
Macro	—	—	6.67%	12.81%

Earnings· Feb 7

McKesson Corporation reported Q3 2024 earnings, with adjusted EPS of $7.74 beating the estimate of $7.05.
Revenue for the quarter was $80.9B, beating the estimated $77.86B.
The company raised its full-year guidance for adjusted EPS to $27.25-$27.65, from the previous estimate of $26.80-$27.40.

Analysts· Dec 9

Bank of America raised McKesson's PT to $265 with a buy rating.
Barclays analyst Steve Valiquette maintained McKesson with an Overweight rating and raised the price target from $270 to $290.
Robert W. Baird raised McKesson's PT to $300 with an outperform rating.

Announcements· May 7

McKesson Corporation reported Q1 2024 earnings with revenues at $76.4 billion, missing the estimated $79.17 billion.
The company's adjusted EPS came in at $6.18, below the estimated $6.31.
McKesson's stock price declined by 1.05% in after-hours trading following the earnings release.

Controversies· Jul 20

McKesson Corporation ($MCK) is involved in a $1.1 billion opioid settlement with New York Attorney General.
$MCK and other distributors are near a $26 billion opioid settlement with the US government.
McKesson ($MCK) is mentioned alongside Johnson & Johnson (JNJ) as a favored stock on the Street due to the impending settlement.

Technical Analysis· Oct 26

The current level of support for MCK is around $146.74, with a deeper support level at $145.13.
MCK's level of support at $145.37 was defended, but the daily support level at $145.13 remains a concern.
The LOD (low of the day) for MCK is $147.26, which is a key level to watch for potential support.

Generated by AI

Community

Of the messages about MCK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	20.75%	36.82%
Newcomers	—	—	79.25%	63.18%

Regulars· Feb 4

McKesson Corporation's Q3 2026 earnings report exceeded expectations, with revenue of $106.2 billion, a 11% year-over-year increase, and adjusted earnings per share (EPS) of $9.34, a 16% year-over-year increase.
The company's GAAP EPS was $9.59, a 38% increase year-over-year, and its quarterly consolidated revenues of $106.2 billion increased 11% year-over-year.
McKesson raised its fiscal year 2026 adjusted EPS guidance to $38.80-$39.20, a 17-19% growth, following the strong Q3 earnings report, driven by surging oncology growth and consistent execution.

Newcomers· Jan 30

The newcomer is impressed by MCK's performance in a down market, citing its oligopoly status as a reason for its success.
The newcomer has invested in MCK due to its large total addressable market (TAM) and monopoly-like market position, which is expected to drive accelerating revenue and expanding margins.
MCK's position as the #1 seat at the table in its oligopoly is seen as a key factor in its unfair advantage, making it an attractive investment opportunity.

Generated by AI

McKesson

Social

Aug 25

Bullish· Feb 5

Bearish· Aug 8

Earnings· Feb 7

Analysts· Dec 9

Announcements· May 7

Controversies· Jul 20

Technical Analysis· Oct 26

Regulars· Feb 4

Newcomers· Jan 30

McKesson Corp. stock underperforms Thursday when compared to competitors

Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years - McKesson (NYSE:MCK)

Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?

Why McKesson (MCK) Dipped More Than Broader Market Today

McKesson Corp. stock outperforms competitors despite losses on the day

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Also Discussed

McKesson Corporation

Company Information

Location

McKesson Corp. stock underperforms Thursday when compared to competitors

Here’s How Much You Would Have Made Owning McKesson Stock In The Last 5 Years - McKesson (NYSE:MCK)

Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?

Why McKesson (MCK) Dipped More Than Broader Market Today

McKesson Corp. stock outperforms competitors despite losses on the day

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

Also Discussed

Social

Aug 25

Bullish· Feb 5

Bearish· Aug 8

Earnings· Feb 7

Analysts· Dec 9

Announcements· May 7

Controversies· Jul 20

Technical Analysis· Oct 26

Regulars· Feb 4

Newcomers· Jan 30